MTVA Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

MetaVia Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerMTVA

Market Cap14.3M

Cash RunwayRunway > 12 months

Next Catalyst2026-11-09

Public Research Snapshot

MetaVia Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for DA-1726 in Obesity (Phase 1).

Pipeline

Asset	Indication	Modality	Stage	Public Note
DA-1726	Obesity	n/a	Phase 1	Public pipeline row

Catalyst Preview

Company	Ticker	Catalyst	Timing	Asset	Confidence
		Clinical Trial Completion	2026-11-09	DA-1726	Low

Cash Runway Preview

Estimated cash runway: Runway > 12 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT06252220	Phase 1	RECRUITING	139	2026-11-09

Scientific Context

asset_name | DA-1726
catalyst_date_estimated | 2026-11-09
catalyst_type | Clinical Trial Completion
clinical_stage | Phase 1
clinical_stage | Phase 1

Want the full MTVA research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.